Back to News
Market Impact: 0.25
FDA Accepts Bayer's Filing To Expand KERENDIA Use In CKD Without Diabetes
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The U.S. FDA accepted Bayer’s supplemental New Drug Application for KERENDIA (finerenone) to treat adults with non-diabetic chronic kidney disease. Acceptance is a regulatory review milestone, not an approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
BAYN0.55
More News
- Roche Gets FDA Approval for Another Label Expansion of Tecentriq
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- SpaceX to buy key spectrum that could help Starlink Mobile become major US cell carrier
- Why is the Chinese stock market missing the AI rally
- Why is T-Mobile stock tumbling today?